✦ LIBER ✦

PAR3 COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS IN ARGENTINA

✍ Scribed by JP Solé; GP Ortega; A Kielhorn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB

✍ B Mistry; J McCormick; A Diamantopoulos; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PAR10 COST-EFFECTIVENESS OF RITUXIMAB TH

✍ A Kielhorn; A Rubbert; D Porter; S De Vita; B Brown; M Aristides; R Aultman; F J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PAR7 MODELLING OF THE COST-EFFECTIVENESS

✍ S De Vita; G Giuliani; A Diamantopoulos; B Brown; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PAR5 COST-EFFECTIVENESS OF RITUXIMAB AS

✍ A Rubbert; A Kielhorn; S Schach; B Brown 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PAR20 BENEFIT-RISK-COST TRADE-OFF ANALYS

✍ RV Arjunji; OH Dabbous; Ml Rahman 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PMS11 COST-EFFECTIVENESS ANALYSIS OF RIT

✍ SF Lou; DY Chen; TT Cheng; CM Huang; HY Lin; CC Su; WC Tsai; JC Tseng; CC Wei; L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB